Skye Bioscience stockholders approve 3x increase in authorized common shares to 300M

On May 28, 2026, Skye Bioscience, Inc., a Nevada corporation (the “Company”) filed a Certificate of Amendment to the Company’s Articles of Incorporation (the “Articles”) with the Nevada Secretary of State, to amend Section 1 of Article IV of the Articles to increase the number of authorized shares of common stock, par value $0.001 per share (the “common stock”), of the Company from 100,000,000 to 300,000,000 (the “Charter Amendment”).

Proposal No. 2 : The ratification of the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The selection was ratified by the votes indicated: For Against Abstain 22,802,045 542,634 184,745

Proposal No. 3 : The approval of the Charter Amendment. The Charter Amendment was approved by the votes indicated: For Against Abstain 20,594,286 2,875,605 59,533

Proposal No. 1: Election of Directors. The stockholders elected each of the six nominees named in the proxy statement for the 2026 Annual Meeting (the “Proxy Statement”) as members of the Board of Directors for a one-year term expiring at the Company’s 2027 annual meeting of stockholders. The results were as follows: Broker Director For Withhold Non-Votes Paul Grayson 13,194,721 511,577 9,823,126 Deborah Charych 13,293,551 412,747 9,823,126 Punit Dhillon 13,466,198 240,100 9,823,126 Annalisa Jenkins 13,491,428 214,870 9,823,126 Karen Smith 13,036,640 669,658 9,823,126 Andrew J. Schwab 13,408,440 297,858 9,823,126

Proposal No. 4 : The approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The compensation of the named executive officers was approved, on an advisory basis, by the votes indicated: For Against Abstain Broker Non-Votes 12,696,055 909,925 100,318 9,823,126